mRNA Vaccine Slows Melanoma Recurrence
Unknown authors
Abstract
Findings from the phase IIb KEYNOTE-942 trial indicate that the investigational vaccine mRNA-4157/V940 plus pembrolizumab is a potential adjuvant therapy for high-risk melanoma. Following surgery, patients who received the combination experienced a significant reduction in disease recurrence risk, compared with those given just PD-1 inhibitor.
Topics & Concepts
PembrolizumabMelanomaAdjuvantMedicineOncologyAdjuvant therapyInternal medicineDiseaseImmunotherapyCancer researchCancerCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy research